牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has reported the exercise of pre-funded warrants on March 6 and 7, 2024, resulting in the issuance of 72,000 and 62,000 shares of common stock, respectively. This follows the company's 1-for-19 reverse stock split effective on February 28, 2024. The transactions, which involved an aggregate cash amount of $254.60, were exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following these exercises, the company announced that no pre-funded warrants remain outstanding and the total issued and outstanding common stock amounts to approximately 852,758 shares. The resale of the shares was registered under a registration statement declared effective under the Securities Act. The information was disclosed in a Form 8-K filed with the SEC, signed by CEO James N. Woody, M.D., Ph.D., on March 8, 2024.
180 Life Sciences Corp. has reported the exercise of pre-funded warrants on March 6 and 7, 2024, resulting in the issuance of 72,000 and 62,000 shares of common stock, respectively. This follows the company's 1-for-19 reverse stock split effective on February 28, 2024. The transactions, which involved an aggregate cash amount of $254.60, were exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following these exercises, the company announced that no pre-funded warrants remain outstanding and the total issued and outstanding common stock amounts to approximately 852,758 shares. The resale of the shares was registered under a registration statement declared effective under the Securities Act. The information was disclosed in a Form 8-K filed with the SEC, signed by CEO James N. Woody, M.D., Ph.D., on March 8, 2024.
180 Life Sciences Corp. 報告稱，2024年3月6日和7日行使了預先注資的認股權證，分別發行了72,000股和62,000股普通股。在此之前，該公司於2024年2月28日生效了19比19的反向股票拆分。根據1933年《證券法》第4（a）（2）條，這些交易涉及的現金總額爲254.60美元，無需註冊。在這些活動之後，該公司宣佈沒有未償還的預先注資認股權證，已發行和流通的普通股總額約爲852,758股。股票的轉售是根據一份根據《證券法》宣佈生效的註冊聲明進行登記的。該信息在向美國證券交易委員會提交的8-K表格中披露，該表格由首席執行官詹姆斯·伍迪醫學博士、博士於2024年3月8日簽署。
180 Life Sciences Corp. 報告稱，2024年3月6日和7日行使了預先注資的認股權證，分別發行了72,000股和62,000股普通股。在此之前，該公司於2024年2月28日生效了19比19的反向股票拆分。根據1933年《證券法》第4（a）（2）條，這些交易涉及的現金總額爲254.60美元，無需註冊。在這些活動之後，該公司宣佈沒有未償還的預先注資認股權證，已發行和流通的普通股總額約爲852,758股。股票的轉售是根據一份根據《證券法》宣佈生效的註冊聲明進行登記的。該信息在向美國證券交易委員會提交的8-K表格中披露，該表格由首席執行官詹姆斯·伍迪醫學博士、博士於2024年3月8日簽署。
有用
沒用